Bayer Aktienges Ads (BAYRY) 144.4400 $BAYRY
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Forget Gilead Sciences: Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Thu Feb 12, 7:19AM CST
A doubling of Gilead Sciences ' sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Global Glucose Monitoring Market Report: 2015 Edition
M2 - Wed Feb 11, 10:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2z5b6/global_glucose) has announced the addition of the "Global Glucose Monitoring Market Report: 2015 Edition" report to their offering. The key factors which are anticipated to drive the market include factors like increasing aging population, rising healthcare expenditure, increasing urbanization, obese population and awareness about blood glucose monitoring. Some of the noteworthy developments of this industry include sedentary lifestyle, increasing prevalence of diabetes, among others. However, the growth of respective industry is hindered by the barriers of regulatory risk, intense competition, and non-invasive blood glucose monitoring, among others. This report offers a comprehensive analysis of the global glucose monitoring industry. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global glucose monitoring market is reined by few major players namely, Johnson and Johnson, Bayer, Roche and Abbott. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Featured: - Johnson and Johnson - Abbott Laboratories - Roche Holdings AG - Bayer AG For more information visit http://www.researchandmarkets.com/research/q2...al_glucose
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Regeneron Pharmaceuticals Inc. Earnings: All Eyes on Eylea
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 10:35AM CST
Regeneron Pharmaceuticals reported its fourth-quarter numbers before the bell this morning, slightly missing consensus on diluted earnings per share but beating on revenue. The Street expected diluted EPS of $2.82, but the company posted...
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:28AM CST
Regeneron Pharmaceuticals (REGN) reported fourth-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.16 per share.
ALNY: 95.54 (+1.67), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 2:20PM CST
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release its fourth-quarter 2014 financial results before the opening bell on Feb 10, 2015.
ACT: 285.37 (+3.71), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Statement from Phillip Blake, President of Bayer Corporation, on FDA Commissioner Margaret Hamburg, M.D.
PR Newswire - Thu Feb 05, 4:35PM CST
"During her nearly six years of leadership at the U.S. Food and Drug Administration, Commissioner Margaret Hamburg has been deeply committed to public health, while working hard to foster an environment for growth in science and innovation throughout the pharmaceutical and medical device industries. FDA has also evolved in the way it engages with industry, which has improved the drug development process and other interactions with the agency. During her tenure, Bayer has been able to introduce seven FDA approved new molecular entities to meet the needs of patients, including those who suffer from rare diseases. On behalf of Bayer and the patients we serve, I congratulate Commissioner Hamburg on a job well done and the strong legacy she leaves behind. We look forward to continuing our work with the new leadership and the rest of the FDA team."
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Global Crop Protection Chemicals Market - (2013-2019)
M2 - Thu Feb 05, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/vzpnzd/global_crop) has announced the addition of the "Global Crop Protection Chemicals Market - (2013-2019)" report to their offering. The ever increasing population growth rate across the globe along with the rise in calorie intake per capita has fueled the demand for food grains. With the advent of new agricultural technologies, the crop production in the world has grown sharply. The significant contribution to this rise is attributed to the large scale induction of pesticides in pre-harvesting crop growth process and post-harvesting storage techniques. Bio-Pesticides according to Environmental Protection Agency, USA are defined as pesticides derived from natural entities like virus, bacteria, animals, plants etc. As of 2013 there are about 400 registered bio-pesticide active ingredients with more than 1250 registered bio-pesticide products. The bio-pesticide is mainly divided into three classes: biochemical pesticides that are naturally occurring substances that control pests by non-toxic mechanisms, microbial pesticides consisting of micro-organisms as active ingredients and plant incorporated protectant pesticides are produced from plants through a genetic material added into them. Chemical or Synthetic Pesticides are the predominant pesticides used excessively for crop protection. The chief pesticides used are categorized into fungicides, herbicides and insecticides. Key Topics Covered: 1. Global Crop Protection - Market Overview 2. Executive Summary 3. Global Crop Protection - Market Landscape 4. Global Crop Protection - Market Forces 5. Global Crop Protection Market- Strategic Analysis 6. Global Crop Protection Market - By Pest Control Nature 7. Global Crop Protection Market - By Type of Crop 8. Global Crop Protection Market - By Geography 9. Market Entropy 10. Company Profiles (Overview, Financials, Developments, Product Portfolio- SWOT Analysis For Top 5 Companies,) 11. Appendix Companies Mentioned: - AG Biochem Inc. - AG Biotech Australia Pty. Ltd. - Agraquest Inc. - BASF SE - Bayer AG - Dow Agrosciences LLC - EI DuPont De Nemours and Co. - Monsanto Co. - Potash Corp. SAS Inc. - Syngenta AG - Troy Biosciences Inc. - Valent Biosciences Corp. For more information visit http://www.researchandmarkets.com/research/vz...lobal_crop
SYT: 70.02 (+0.31), MON: 124.77 (+2.00)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
Merck (MRK) Beats on Q4 Earnings but Guidance Falls Short - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 04, 10:21AM CST
Merck's (MRK) fourth quarter results were better-than-expected but the company's 2015 outlook was well short of expectations.
BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)
Will Merck's (MRK) Q4 Earnings be Hit by Patent Expiries? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 12:50PM CST
Merck & Co. Inc. is scheduled to report its fourth-quarter 2014 results on Feb 4, before the opening bell.
ACT: 285.37 (+3.71), MRK: 58.81 (-0.07), ACOR: 36.14 (-0.51)
This Tiny Biotech Hopes to Capture a Share of This $6 Billion Market
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 7:02AM CST
Source: Flickr user Ali T . Ophthotech Corporation is developing a new drug that may improve results for Novartis and Regeneron 's top-selling vision loss therapies. If Ophthotech's late-stage trials pan out, Ophthotech could have a...
JPM: 59.67 (+0.10), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Sat Jan 31, 9:54AM CST
UTX: 121.25 (+1.66), FBGX: 121.65 (+1.42), SCPB: 30.64 (-0.02), INTC: 34.36 (+0.23), GOOG: 549.01 (+6.08), SLB: 88.38 (+2.42), JPM: 59.67 (+0.10), HDB: 58.41 (-0.98), MBB: 109.88 (+0.03), LYG: 4.60 (+0.04), MSFT: 43.87 (+0.78), CSCO: 29.43 (-0.03), BCS: 15.77 (+0.12), PFE: 34.64 (-0.23), WFC: 55.33 (+0.47), GSK: 47.94 (+1.99), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), CVX: 112.78 (+1.92), BRK.B: 148.34 (-1.45), NVS: 102.20 (-0.17), GE: 25.15 (+0.26), C: 51.20 (+0.31), XOM: 93.37 (+1.00), TM: 132.49 (+0.67), FIGY: 123.46 (+0.84), PEP: 99.13 (-1.14), JNJ: 99.62 (+1.18), AAWW: 48.01 (+0.44), V: 269.63 (-1.28), SAP: 69.09 (unch), QCOM: 70.88 (+0.49), GOOGL: 551.16 (+5.15), SNY: 49.42 (+0.82), AAPL: 127.08 (+0.62), KO: 41.99 (-0.18), AMZN: 381.83 (+4.66), HD: 111.89 (-0.27), AXP: 78.08 (-2.40), FEEU: 111.93 (+1.22), CS: 23.65 (+0.23), DIS: 104.17 (+0.59), HSBC: 46.13 (-0.01), TSM: 24.84 (+0.37), BAC: 16.61 (-0.06), ORCL: 43.93 (+0.04), HPY: 49.42 (-5.71), LQD: 120.83 (-0.48), RY: 62.26 (+0.23), PG: 85.90 (-0.13), CMCSA: 59.47 (+1.09), FLGE: 121.40 (+1.48)
Opko files IND for study of long-acting clotting factor
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:31AM CST
BIIB: 391.66 (-0.45), ALNY: 95.54 (+1.67), OPK: 13.80 (-0.28), BAX: 70.39 (+0.31), SGMO: 15.40 (+0.14)
Cardinal Health (CAH) Tops Q2 Earnings on Strong Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:33AM CST
Cardinal Health, Inc.'s (CAH) second-quarter fiscal 2015 earnings of $1.20 per share surged 33.3% year over year riding on strong revenue growth.
CAH: 86.08 (+0.04), CVS: 102.63 (-0.37), HSIC: 143.18 (+0.72)
Global Plastics Additives Market (Functions, Product Types, Applications, Geography) - Global Industry Analysis, Size, Growth Trends, Share, Opportunities and Forecast 2012 - 2020
PR Newswire - Thu Jan 22, 9:10AM CST
Plastics additives are the substances that are added in polymer during reaction in the final stage or in the process of polymer/plastic production. These additives help in improving the characteristics of polymers such as strength, shine, durability and heat sensitivity. The global plastic additives market in this report is estimate in terms of revenue and volume. The global plastic additives market was valued for $41.4 billion in 2013 and is expected to generate revenue of $57.8 billion by 2020 at a CAGR of 4.9% during 2013-2020. The global plastic additives market in terms of volume was estimated at 12,619.8 Kilo Tons in 2013 and is expected to reach 17,071.7 Kilo Tons by 2020 growing at a CAGR of 4.4% during 2013-2020. Impacting drivers of plastic additives market such as increase in environmental awareness and intervention by government to promote non-toxic plastic additives is promoting the growth in plastic additives market. However, increase in health concerns due to consumption of Phthalates based plasticizers is forcing the government to harness the regulations for controlling commercialization of such additives. In the United States, the application of phthalates in the manufacturing of toys and other children's product is banned under the guidance of Consumer Products Safety Improvement Act (CPSIA).
CHMT: 24.77 (+0.81)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Forget Gilead Sciences: Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Thu Feb 12, 7:19AM CST
A doubling of Gilead Sciences ' sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Global Glucose Monitoring Market Report: 2015 Edition
M2 - Wed Feb 11, 10:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2z5b6/global_glucose) has announced the addition of the "Global Glucose Monitoring Market Report: 2015 Edition" report to their offering. The key factors which are anticipated to drive the market include factors like increasing aging population, rising healthcare expenditure, increasing urbanization, obese population and awareness about blood glucose monitoring. Some of the noteworthy developments of this industry include sedentary lifestyle, increasing prevalence of diabetes, among others. However, the growth of respective industry is hindered by the barriers of regulatory risk, intense competition, and non-invasive blood glucose monitoring, among others. This report offers a comprehensive analysis of the global glucose monitoring industry. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global glucose monitoring market is reined by few major players namely, Johnson and Johnson, Bayer, Roche and Abbott. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Featured: - Johnson and Johnson - Abbott Laboratories - Roche Holdings AG - Bayer AG For more information visit http://www.researchandmarkets.com/research/q2...al_glucose
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Regeneron Pharmaceuticals Inc. Earnings: All Eyes on Eylea
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 10:35AM CST
Regeneron Pharmaceuticals reported its fourth-quarter numbers before the bell this morning, slightly missing consensus on diluted earnings per share but beating on revenue. The Street expected diluted EPS of $2.82, but the company posted...
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:28AM CST
Regeneron Pharmaceuticals (REGN) reported fourth-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.16 per share.
ALNY: 95.54 (+1.67), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 2:20PM CST
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release its fourth-quarter 2014 financial results before the opening bell on Feb 10, 2015.
ACT: 285.37 (+3.71), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Statement from Phillip Blake, President of Bayer Corporation, on FDA Commissioner Margaret Hamburg, M.D.
PR Newswire - Thu Feb 05, 4:35PM CST
"During her nearly six years of leadership at the U.S. Food and Drug Administration, Commissioner Margaret Hamburg has been deeply committed to public health, while working hard to foster an environment for growth in science and innovation throughout the pharmaceutical and medical device industries. FDA has also evolved in the way it engages with industry, which has improved the drug development process and other interactions with the agency. During her tenure, Bayer has been able to introduce seven FDA approved new molecular entities to meet the needs of patients, including those who suffer from rare diseases. On behalf of Bayer and the patients we serve, I congratulate Commissioner Hamburg on a job well done and the strong legacy she leaves behind. We look forward to continuing our work with the new leadership and the rest of the FDA team."
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Global Crop Protection Chemicals Market - (2013-2019)
M2 - Thu Feb 05, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/vzpnzd/global_crop) has announced the addition of the "Global Crop Protection Chemicals Market - (2013-2019)" report to their offering. The ever increasing population growth rate across the globe along with the rise in calorie intake per capita has fueled the demand for food grains. With the advent of new agricultural technologies, the crop production in the world has grown sharply. The significant contribution to this rise is attributed to the large scale induction of pesticides in pre-harvesting crop growth process and post-harvesting storage techniques. Bio-Pesticides according to Environmental Protection Agency, USA are defined as pesticides derived from natural entities like virus, bacteria, animals, plants etc. As of 2013 there are about 400 registered bio-pesticide active ingredients with more than 1250 registered bio-pesticide products. The bio-pesticide is mainly divided into three classes: biochemical pesticides that are naturally occurring substances that control pests by non-toxic mechanisms, microbial pesticides consisting of micro-organisms as active ingredients and plant incorporated protectant pesticides are produced from plants through a genetic material added into them. Chemical or Synthetic Pesticides are the predominant pesticides used excessively for crop protection. The chief pesticides used are categorized into fungicides, herbicides and insecticides. Key Topics Covered: 1. Global Crop Protection - Market Overview 2. Executive Summary 3. Global Crop Protection - Market Landscape 4. Global Crop Protection - Market Forces 5. Global Crop Protection Market- Strategic Analysis 6. Global Crop Protection Market - By Pest Control Nature 7. Global Crop Protection Market - By Type of Crop 8. Global Crop Protection Market - By Geography 9. Market Entropy 10. Company Profiles (Overview, Financials, Developments, Product Portfolio- SWOT Analysis For Top 5 Companies,) 11. Appendix Companies Mentioned: - AG Biochem Inc. - AG Biotech Australia Pty. Ltd. - Agraquest Inc. - BASF SE - Bayer AG - Dow Agrosciences LLC - EI DuPont De Nemours and Co. - Monsanto Co. - Potash Corp. SAS Inc. - Syngenta AG - Troy Biosciences Inc. - Valent Biosciences Corp. For more information visit http://www.researchandmarkets.com/research/vz...lobal_crop
SYT: 70.02 (+0.31), MON: 124.77 (+2.00)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
Merck (MRK) Beats on Q4 Earnings but Guidance Falls Short - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 04, 10:21AM CST
Merck's (MRK) fourth quarter results were better-than-expected but the company's 2015 outlook was well short of expectations.
BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)
Will Merck's (MRK) Q4 Earnings be Hit by Patent Expiries? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 12:50PM CST
Merck & Co. Inc. is scheduled to report its fourth-quarter 2014 results on Feb 4, before the opening bell.
ACT: 285.37 (+3.71), MRK: 58.81 (-0.07), ACOR: 36.14 (-0.51)
This Tiny Biotech Hopes to Capture a Share of This $6 Billion Market
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 7:02AM CST
Source: Flickr user Ali T . Ophthotech Corporation is developing a new drug that may improve results for Novartis and Regeneron 's top-selling vision loss therapies. If Ophthotech's late-stage trials pan out, Ophthotech could have a...
JPM: 59.67 (+0.10), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Sat Jan 31, 9:54AM CST
UTX: 121.25 (+1.66), FBGX: 121.65 (+1.42), SCPB: 30.64 (-0.02), INTC: 34.36 (+0.23), GOOG: 549.01 (+6.08), SLB: 88.38 (+2.42), JPM: 59.67 (+0.10), HDB: 58.41 (-0.98), MBB: 109.88 (+0.03), LYG: 4.60 (+0.04), MSFT: 43.87 (+0.78), CSCO: 29.43 (-0.03), BCS: 15.77 (+0.12), PFE: 34.64 (-0.23), WFC: 55.33 (+0.47), GSK: 47.94 (+1.99), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), CVX: 112.78 (+1.92), BRK.B: 148.34 (-1.45), NVS: 102.20 (-0.17), GE: 25.15 (+0.26), C: 51.20 (+0.31), XOM: 93.37 (+1.00), TM: 132.49 (+0.67), FIGY: 123.46 (+0.84), PEP: 99.13 (-1.14), JNJ: 99.62 (+1.18), AAWW: 48.01 (+0.44), V: 269.63 (-1.28), SAP: 69.09 (unch), QCOM: 70.88 (+0.49), GOOGL: 551.16 (+5.15), SNY: 49.42 (+0.82), AAPL: 127.08 (+0.62), KO: 41.99 (-0.18), AMZN: 381.83 (+4.66), HD: 111.89 (-0.27), AXP: 78.08 (-2.40), FEEU: 111.93 (+1.22), CS: 23.65 (+0.23), DIS: 104.17 (+0.59), HSBC: 46.13 (-0.01), TSM: 24.84 (+0.37), BAC: 16.61 (-0.06), ORCL: 43.93 (+0.04), HPY: 49.42 (-5.71), LQD: 120.83 (-0.48), RY: 62.26 (+0.23), PG: 85.90 (-0.13), CMCSA: 59.47 (+1.09), FLGE: 121.40 (+1.48)
Opko files IND for study of long-acting clotting factor
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:31AM CST
BIIB: 391.66 (-0.45), ALNY: 95.54 (+1.67), OPK: 13.80 (-0.28), BAX: 70.39 (+0.31), SGMO: 15.40 (+0.14)
Cardinal Health (CAH) Tops Q2 Earnings on Strong Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:33AM CST
Cardinal Health, Inc.'s (CAH) second-quarter fiscal 2015 earnings of $1.20 per share surged 33.3% year over year riding on strong revenue growth.
CAH: 86.08 (+0.04), CVS: 102.63 (-0.37), HSIC: 143.18 (+0.72)
Global Plastics Additives Market (Functions, Product Types, Applications, Geography) - Global Industry Analysis, Size, Growth Trends, Share, Opportunities and Forecast 2012 - 2020
PR Newswire - Thu Jan 22, 9:10AM CST
Plastics additives are the substances that are added in polymer during reaction in the final stage or in the process of polymer/plastic production. These additives help in improving the characteristics of polymers such as strength, shine, durability and heat sensitivity. The global plastic additives market in this report is estimate in terms of revenue and volume. The global plastic additives market was valued for $41.4 billion in 2013 and is expected to generate revenue of $57.8 billion by 2020 at a CAGR of 4.9% during 2013-2020. The global plastic additives market in terms of volume was estimated at 12,619.8 Kilo Tons in 2013 and is expected to reach 17,071.7 Kilo Tons by 2020 growing at a CAGR of 4.4% during 2013-2020. Impacting drivers of plastic additives market such as increase in environmental awareness and intervention by government to promote non-toxic plastic additives is promoting the growth in plastic additives market. However, increase in health concerns due to consumption of Phthalates based plasticizers is forcing the government to harness the regulations for controlling commercialization of such additives. In the United States, the application of phthalates in the manufacturing of toys and other children's product is banned under the guidance of Consumer Products Safety Improvement Act (CPSIA).
CHMT: 24.77 (+0.81)
